Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $.001 per share
-
Shares outstanding
-
31.8M
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
314K
-
Shares change
-
+33.7K
-
Total reported value, excl. options
-
$1.1M
-
Value change
-
+$118K
-
Number of buys
-
2
-
Number of sells
-
-2
-
Price
-
$3.52
Significant Holders of Moleculin Biotech, Inc. - Common Stock, par value $.001 per share (MBRX) as of Q2 2024
16 filings reported holding MBRX - Moleculin Biotech, Inc. - Common Stock, par value $.001 per share as of Q2 2024.
Moleculin Biotech, Inc. - Common Stock, par value $.001 per share (MBRX) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 314K shares
of 31.8M outstanding shares and own 0.99% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (156K shares), VANGUARD GROUP INC (84.4K shares), LPL Financial LLC (33.8K shares), GEODE CAPITAL MANAGEMENT, LLC (19.8K shares), BlackRock Inc. (12.5K shares), ATTICUS WEALTH MANAGEMENT, LLC (3.33K shares), Tower Research Capital LLC (TRC) (2K shares), Newbridge Financial Services Group, Inc. (1.37K shares), MORGAN STANLEY (426 shares), and Sandy Spring Bank (89 shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.